A historic moment: WHO recommends deployment of a malaria vaccine finally developed after a 100-year endeavour. The WHO have advised that the RTS,S/AS01 vaccine, also known as Mosquirix, developed by GlaxoSmithKline (London, England) over the last 30 years in…
Browsing: Parasitic > Malaria
Scientists from Imperial College London (UK) and the Wellcome Sanger Institute (Cambridge, UK) have mapped the genetic changes malaria parasites…
Malara parasites showing artemisinin resistance previously seen in South-East Asia have recently emerged in areas of Rwanda in Sub-Saharan Africa. If the mutation causing resistance becomes prevalent across the continent it could have major public health impacts.
In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Upon investigating links between the risk of malaria in developing countries and the products demanded by consumers worldwide, researchers have estimated that a significant fraction of the malaria risk in deforestation hotspots is driven by the international trade of products.
The WHO has published 2019’s World Malaria Report, providing an update on global trends and highlighting pregnant women and children as particularly at-risk groups.
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
Published in Nature, new research elucidates the mechanism behind malarial resistance to piperaquine and suggests how this knowledge could be used to combat its spread.
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and a rapid diagnostic test for…